GENPHARMATrading & Distributors
Genpharmasec Ltd — Profit & Loss Statement
₹0.78
-7.69%
Genpharmasec Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.05 Cr | 0.21 Cr | — |
| Tax Rate For Calcs | 0.39 | 0.30 | 0.30 | 0.30 | — |
| Normalized EBITDA | 3.13 Cr | 0.70 Cr | 0.20 Cr | -1.14 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Reconciled Depreciation | 0.81 Cr | 0.04 Cr | 0.02 Cr | 0.01 Cr | — |
| Reconciled Cost Of Revenue | 29.55 Cr | 24.23 Cr | 23.40 Cr | 26.57 Cr | — |
| EBITDA | 3.13 Cr | 0.70 Cr | 0.36 Cr | -0.43 Cr | — |
| EBIT | 2.31 Cr | 0.66 Cr | 0.34 Cr | -0.44 Cr | — |
| Net Interest Income | -0.43 Cr | -0.41 Cr | -0.03 Cr | 0.07 Cr | — |
| Interest Expense | 0.43 Cr | 0.41 Cr | 0.06 Cr | 0.00 | — |
| Normalized Income | 1.23 Cr | -0.17 Cr | 1.01 Cr | -0.71 Cr | — |
| Net Income From Continuing And Discontinued Operation | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Total Expenses | 31.35 Cr | 25.04 Cr | 25.21 Cr | 27.86 Cr | — |
| Diluted Average Shares | 55.37 Cr | 55.37 Cr | 46.11 Cr | 46.11 Cr | — |
| Basic Average Shares | 55.37 Cr | 55.37 Cr | 46.11 Cr | 46.11 Cr | — |
| Diluted EPS | 0.01 | 0.01 | 0.02 | -0.01 | — |
| Basic EPS | 0.01 | 0.01 | 0.02 | -0.01 | — |
| Diluted NI Availto Com Stockholders | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Net Income Common Stockholders | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Net Income Including Noncontrolling Interests | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Net Income Continuous Operations | 1.23 Cr | -0.17 Cr | 1.12 Cr | -0.21 Cr | — |
| Tax Provision | 0.73 Cr | 0.42 Cr | -0.84 Cr | -0.23 Cr | — |
| Pretax Income | 1.88 Cr | 0.25 Cr | 0.28 Cr | -0.44 Cr | — |
| Other Non Operating Income Expenses | -0.06 Cr | -4.71 Cr | 0.01 Cr | 0.01 Cr | — |
| Net Non Operating Interest Income Expense | -0.43 Cr | -0.41 Cr | -0.03 Cr | 0.07 Cr | — |
| Interest Expense Non Operating | 0.43 Cr | 0.41 Cr | 0.06 Cr | 0.00 | — |
| Operating Income | 2.37 Cr | 5.37 Cr | 0.08 Cr | -1.24 Cr | — |
| Operating Expense | 1.80 Cr | 0.81 Cr | 1.81 Cr | 1.29 Cr | — |
| Depreciation And Amortization In Income Statement | 0.81 Cr | 0.04 Cr | 0.02 Cr | 0.01 Cr | — |
| Depreciation Income Statement | 0.81 Cr | 0.04 Cr | 0.02 Cr | 0.01 Cr | — |
| Gross Profit | 4.17 Cr | 6.17 Cr | 1.89 Cr | 0.05 Cr | — |
| Cost Of Revenue | 29.55 Cr | 24.23 Cr | 23.40 Cr | 26.57 Cr | — |
| Total Revenue | 33.72 Cr | 30.41 Cr | 25.28 Cr | 26.61 Cr | — |
| Operating Revenue | 33.72 Cr | 30.41 Cr | 25.28 Cr | 26.61 Cr | — |
| Total Unusual Items | — | -0.51 Cr | 0.16 Cr | 0.71 Cr | 0.51 Cr |
| Total Unusual Items Excluding Goodwill | — | -0.51 Cr | 0.16 Cr | 0.71 Cr | 0.51 Cr |
| Interest Income | — | 0.47 Cr | 0.03 Cr | 0.07 Cr | 0.33 Cr |
| Rent Expense Supplemental | — | 0.15 Cr | 0.15 Cr | 0.10 Cr | 0.10 Cr |
| Minority Interests | — | 0.04 Cr | 0.00 | — | — |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income Charges | — | -0.51 Cr | -0.07 Cr | 0.00 | 0.00 |
| Other Special Charges | — | 0.09 Cr | — | — | — |
| Write Off | — | 0.42 Cr | 0.07 Cr | — | — |
| Interest Income Non Operating | — | 0.47 Cr | 0.03 Cr | 0.07 Cr | 0.33 Cr |
| Other Operating Expenses | — | 4.08 Cr | 0.71 Cr | 0.51 Cr | 0.41 Cr |
| Selling General And Administration | — | 0.59 Cr | 0.38 Cr | 0.39 Cr | 0.20 Cr |
| Selling And Marketing Expense | — | 0.48 Cr | 0.07 Cr | — | — |
| General And Administrative Expense | — | 0.12 Cr | 0.31 Cr | 0.39 Cr | 0.20 Cr |
| Rent And Landing Fees | — | 0.15 Cr | 0.15 Cr | 0.10 Cr | 0.10 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Genpharmasec Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.